The IPO Buzz: Csquare (CSQR) Prices IPO at $21 – $2 Below Range
Csquare, Inc. (CSQR) priced its IPO at $21.00 – $2.00 below the bottom of its range – and sold 50 million shares – the number in the prospectus – to raise $1.05 billion on Wednesday night, July 15, 2026. Bloomberg reported that the IPO had been priced at $21.00 early Wednesday evening, quoting “people familiar with the matter.” But Csquare did not announce the pricing until after midnight when its press release went out online.
Bankers had marketed Csquare’s IPO at a price range of $23.00 to $27.00 – on 50 million shares – to raise $1.25 billion – assuming pricing at the $25.00 mid-point.
At the below-range pricing at $21.00 – Csquare had a market cap of $3.25 billion.
Morgan Stanley, TD Securities, Wells Fargo Securities. BofA Securities, BMO Capital Markets and Scotiabank led the joint book-running team for Csquare’s IPO.
Jefferies, J.P. Morgan, RBC Capital Markets and Societe Generale also served as book-runners, according to the prospectus.
Data on The Map
Csquare owns and operates 64 data centers in 21 major metro markets in the U.S., Canada and the U.K.
A map in the prospectus tells the story: Eight data centers in Silicon Valley, six in Northern Virginia (Washington, D.C., area), five in Dallas, and four each in New Jersey, Chicago, Phoenix and Seattle – as well as three sites each in Boston and Nashville plus two apiece in Los Angeles, Denver, Atlanta and Raleigh, N.C. These metro areas each have one data center: Albuquerque, Tulsa, Minneapolis, Columbus, Ohio, and Tampa. The map omits “three sites currently slated for closure,” the prospectus said.
Outside the U.S., Csquare has six data centers in Canada – three each in the Toronto and Montreal metro areas – and one in London.
Csquare is based in the Big D – in the North Dallas suburb of Coppell, Texas.
Rivers of Red Ink
The IPO pros said that Csquare’s high debt load – about $5 billion outstanding at March 31, 2026 – and its large net loss were red flags.
Csquare intends to use the IPO’s proceeds to pay off $1.17 billion in debt, the prospectus said.
Brookfield of Canada will still control Csquare after the IPO, according to the prospectus. After the IPO, Brookfield’s stake in Csquare would represent about 67.1 percent of the voting power of its outstanding common stock, the prospectus said.
Csquare’s net loss amounted to about 14.8 percent of its revenue for the 12 months that ended on March 31, 2026, according to the prospectus:
Financial Snapshot: Net loss of $150.94 million on revenue of $1.02 billion for the 12 months that ended on March 31, 2026
(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Source: https://www.iposcoop.com/the-ipo-buzz-csquare-csqr-prices-ipo-at-21-2-below-range/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

